术前新辅助化疗及肠内营养对胃癌患者Akt1、Bcl-2、Bax蛋白表达的影响

目的探讨术前新辅助化疗(NAD)及肠内营养(EA)对胃癌患者胃癌组织内Akt1、Bcl-2、Bax蛋白影响。方法选取胃癌患者75例,随机分为对照组25例、NAD组25例和NAD+EA组25例,分别检测干预治疗前后胃癌组织中Akt1、Bcl-2、Bax蛋白的表达情况。结果 NAD组及NAD+EA组治疗后Akt1蛋白含量均较治疗前均显著降低(P<0.05),NAD组及NAD+EA组治疗后Akt1蛋白含量均较对照组显著降低(P<0.05)。NAD组及NAD+EA组治疗后Bcl-2蛋白含量均较治疗前均显著降低(P<0.05),Bax蛋白含量均较治疗前均显著升高(P<0.05),NAD组治疗后Bcl-2蛋白含量较对照组显著降低(P<0.05),NAD+EA组治疗后Bcl-2蛋白含量较对照组显著降低(P<0.01),NAD组及NAD+EA组治疗后Bax蛋白含量均较对照组显著升高(P<0.05)。结论术前NAD结合EA能降低胃癌组织内Akt1、Bcl-2蛋白,提高Bax蛋白水平,可能通过改变蛋白含量抑制肿瘤进程。

Objective To evaluate the effect of of neoadjuvant chemotherapy combined with enteral nutrition on Akt1, Bcl-2, Bax protein in patients with gastric cancer. Methods 75 patients with gastric cancer were randomly divided into the control group （n=25）, neoadjuvant chemotherapy group （NAD group, n=25） and neoadjuvant chemotherapy plus enteral nutrition group （NAD＋EA group, n=25）. The content of Akt1, Bcl-2, Bax protein in gastricancer tissue were detected by westernblot before and after treatment. Results The content of Akt1 were decreased after treatment in NAD group and NAD＋EA group than before treatment（P〈0.05）. The content of Akt1 were decreased after treatment in NAD group and NAD＋EA group than control group （P〈0.05）. The content of Bcl-2 were decreased after treatment in NAD group and NAD＋EA group than before treatment （P〈0.05）. The content of Bax were increased after treatment in NAD group and NAD＋EA group than before treatment （P〈0.05）. The content of Bcl-2 were decreased after treatment in NAD group than control group （P〈0.05）. The content of Bcl-2 were decreased after treatment in NAD＋EA group than control group （P〈0.01）. The content of Bax were increased after treatment in NAD group and NAD＋EA group than control group （P〈0.05）. Conclusion Preoperative neoadjuvant chemotherapy combined with enteral nutrition can decrease the content of Akt1, Bcl-2, increase the Bax protein, the inhibition of tumor procession may realize by changing the protein content.